Literature DB >> 15893406

CSF hypocretin-1/orexin-A concentrations in patients with subarachnoid hemorrhage (SAH).

K Dohi1, B Ripley, N Fujiki, H Ohtaki, S Shioda, T Aruga, S Nishino.   

Abstract

The aim of this study was to examine the role of the hypothalamic hypocretin/orexin system in complications of delayed ischemic neuronal deficit (DIND) resulting from symptomatic vasospasm in patients with aneurysmal subarachnoid hemorrhage (SAH). CSF hypocretin-1/orexin-A levels were measured in 15 SAH patients. DIND complications occurred in seven patients with symptomatic vasospasm. Hypocretin-1/orexin-A levels were low in SAH patients during the 10 days following the SAH event. CSF hypocretin-1/orexin-A levels were lower in patients with DIND complications than in those who did not develop DIND. A significant transient decline in CSF hypocretin-1/orexin-A levels was also observed at the onset of DIND in all patients with symptomatic vasospasm. The reduced hypocretin/orexin production observed in SAH patients may reflect reduced brain function due to the decrease in cerebral blood flow. These results, taken together with recent experimental findings in rats that indicate hypocretin receptor 1 (orexin 1 receptor) mRNA and protein are elevated following middle cerebral artery occlusion, suggest that a reduction in hypocretin/orexin production in SAH and DIND patients is associated with alterations in brain hypocretin/orexin signaling in response to ischemia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15893406     DOI: 10.1016/j.peptides.2005.04.004

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  8 in total

1.  Recovery from Coma Post-Cardiac Arrest Is Dependent on the Orexin Pathway.

Authors:  Young-Jin Kang; Guilian Tian; Afsheen Bazrafkan; Maryam H Farahabadi; Matine Azadian; Hamidreza Abbasi; Brittany E Shamaoun; Oswald Steward; Yama Akbari
Journal:  J Neurotrauma       Date:  2017-06-16       Impact factor: 5.269

2.  Expression and localization of the orexin-1 receptor (OX1R) after traumatic brain injury in mice.

Authors:  Yuko Mihara; Kenji Dohi; Sachiko Yofu; Tomoya Nakamachi; Hirokazu Ohtaki; Seiji Shioda; Tohru Aruga
Journal:  J Mol Neurosci       Date:  2010-08-28       Impact factor: 3.444

3.  Mitigation of murine focal cerebral ischemia by the hypocretin/orexin system is associated with reduced inflammation.

Authors:  Xiaoxing Xiong; Robin E White; Lijun Xu; Liya Yang; Xiaoyun Sun; Bende Zou; Conrado Pascual; Takeshi Sakurai; Rona G Giffard; Xinmin Simon Xie
Journal:  Stroke       Date:  2013-01-24       Impact factor: 7.914

4.  Effect of orexin-a on ischemia-reperfusion-induced gastric damage in rats.

Authors:  Mehmet Bülbül; Ruken Tan; Burcu Gemici; Gözde Ongüt; V Nimet Izgüt-Uysal
Journal:  J Gastroenterol       Date:  2008-03-29       Impact factor: 7.527

5.  Orexin A decreases lipid peroxidation and apoptosis in a novel hypothalamic cell model.

Authors:  Tammy A Butterick; Joshua P Nixon; Charles J Billington; Catherine M Kotz
Journal:  Neurosci Lett       Date:  2012-07-11       Impact factor: 3.046

6.  Low-intensity focused ultrasound attenuates early traumatic brain injury by OX-A/NF-κB/NLRP3 signaling pathway.

Authors:  Lianghua Huang; Junwei Kang; Gengfa Chen; Wen Ye; Xiangqiang Meng; Qing Du; Zhen Feng
Journal:  Aging (Albany NY)       Date:  2022-09-16       Impact factor: 5.955

Review 7.  The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases.

Authors:  Chunmei Wang; Qinqin Wang; Bingyuan Ji; Yanyou Pan; Chao Xu; Baohua Cheng; Bo Bai; Jing Chen
Journal:  Front Mol Neurosci       Date:  2018-06-28       Impact factor: 5.639

8.  Orexin A alleviates neuroinflammation via OXR2/CaMKKβ/AMPK signaling pathway after ICH in mice.

Authors:  Tao Li; Weilin Xu; Jinsong Ouyang; Xiaoyang Lu; Prativa Sherchan; Cameron Lenahan; Giselle Irio; John H Zhang; Jianhua Zhao; Yongfa Zhang; Jiping Tang
Journal:  J Neuroinflammation       Date:  2020-06-15       Impact factor: 8.322

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.